Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

Completed · Phase 3

Conditions studied: Crohn's Disease

In brief

This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).

Key facts

Study ID

NCT00356408

Run by

UCB Pharma

People needed

106

Starts

2007-01-01

Expected to finish

2010-02-01

Last updated by the study team

2018-08-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients previously enrolled in C87059 (COSPAR I, NCT00349752)

You may not qualify if…

• Subject withdrawn or discontinued from C87059 (COSPAR I, NCT00349752) study under specific conditions
• Subject who received treatment other than study medication and other than medications permitted in C87059 (COSPAR I, NCT00349752)
• Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment

Where it is running

• Study site — Montgomery, Alabama, United States
• Study site — La Jolla, California, United States
• Study site — Oceanside, California, United States
• Study site — Palo Alto, California, United States
• Study site — Roseville, California, United States
• Study site — Lakewood, Colorado, United States
• Study site — Clearwater, Florida, United States
• Study site — Gainesville, Florida, United States
• Study site — Hialeah, Florida, United States
• Study site — Jacksonville, Florida, United States
• Study site — North Miami Beach, Florida, United States
• Study site — Marietta, Georgia, United States
• Study site — Savannah, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Bloomington, Indiana, United States
• Study site — Davenport, Iowa, United States
• Study site — Topeka, Kansas, United States
• Study site — Bowling Green, Kentucky, United States
• Study site — Louisville, Kentucky, United States
• Study site — Metairie, Louisiana, United States
• Study site — Annapolis, Maryland, United States
• Study site — Newton, Massachusetts, United States
• Study site — Chesterfield, Michigan, United States
• Study site — Dearborn, Michigan, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.